cgoncology_cover.jpg
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
30 août 2024 08h00 HE | CG Oncology Inc.
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Transparency Market Research
Bladder Cancer Therapeutics Market is Likely to Reach USD 456.3 million by 2034 at a CAGR of 4.8% | Report Analysis by Transparency Market Research Inc.
09 août 2024 10h18 HE | Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research, Inc. , Aug. 09, 2024 (GLOBE NEWSWIRE) -- The global bladder cancer therapeutics market(방광암 치료제 시장) stood at US$ 271.4 million in...
cgoncology_cover.jpg
CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates
08 août 2024 08h23 HE | CG Oncology Inc.
CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates
cgoncology_cover.jpg
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
18 juin 2024 08h00 HE | CG Oncology Inc.
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
cgoncology_cover.jpg
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
06 juin 2024 12h14 HE | CG Oncology Inc.
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab
cgoncology_cover.jpg
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
24 mai 2024 08h00 HE | CG Oncology Inc.
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab
cgoncology_cover.jpg
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
09 mai 2024 08h00 HE | CG Oncology Inc.
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
cgoncology_cover.jpg
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
03 mai 2024 11h23 HE | CG Oncology Inc.
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
cgoncology_cover.jpg
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
24 avr. 2024 10h00 HE | CG Oncology Inc.
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
RactigenLogo.png
Ractigen Therapeutics Advances into Clinical Stage with Groundbreaking saRNA Drug, RAG-01
06 déc. 2023 07h00 HE | Ractigen Therapeutics
This milestone marks Ractigen's transition into clinical development, with RAG-01 targeting NMIBC.